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Hybrid inorganic-organic capsules 
for efficient intracellular delivery of 
novel siRNAs against influenza A 
(H1N1) virus infection
Alexander S. Timin1, Albert R. Muslimov2,3, Aleksandra V. Petrova4, Kirill V. Lepik2, Maria V. 
Okilova2, Andrey V. Vasin4,5, Boris V. Afanasyev2 & Gleb B. Sukhorukov6
The implementation of RNAi technology into the clinical practice has been significantly postponing 
due to the issues regarding to the delivery of naked siRNA predominantly to target cells. Here we 
report the approach to enhance the efficiency of siRNA delivery by encapsulating the siRNA into 
new carrier systems which are obtained via the combination of widely used layer-by-layer technique 
and in situ modification by sol-gel chemistry. We used three types of siRNAs (NP-717, NP-1155 and 
NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infection. By 
employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of 
viral nucleoprotein (NP) level and inhibition of influenza virus production in infected cell lines (MDCK 
and A549). The obtained hybrid carriers based on assembled biodegradable polyelectrolytes and sol-
gel coating possess several advantages such as a high cell uptake efficiency, low toxicity, efficient 
intracellular delivery of siRNAs and the protection of siRNAs from premature degradation before 
reaching the target cells. These findings underpin a great potential of versatile microencapsulation 
technology for the development of anti-viral RNAi delivery systems against influenza virus infection.
Influenza viruses are a significant cause of morbidity and mortality worldwide and can be considered as one 
of the actual problem of international healthcare system. For humans, the influenza type A is the main cause 
for infection outbreaks and pandemics throughout history1. At least 50 million people in various parts of the 
world have died from “Spanish Flu” pandemic that has took place between 1918–1919. Major influenza A 
pandemics occurred in 1957 (“Asian influenza”) and 1968 (“Hong Kong influenza”) caused significant global 
morbidity and mortality. According to the World Health Organization (WHO), it was registered around 608 
laboratory-confirmed human cases of H5N1 avian influenza for the period from 2003 to 20122. A new human 
influenza pandemic could cause 20% of the global population to become affected by this infection3. Therefore, the 
development of new approaches for the efficient treatment of influenza viruses is very important.
At the moment, four licensed influenza antiviral prescription drugs can be used for treatment or prevention of 
influenza4. Oseltamivir and zanamivir are chemical antiviral medications against influenza A and B viruses while 
amantadine and rimantadine are antiviral drugs against only influenza A viruses. However, as influenza virus 
undergoes mutation very rapidly and, therefore, can evolve drug resistance, the efficiency of antiviral drugs can be 
decreased during a flu outbreak5, 6. Due to the possibility of new influenza pandemic, current vaccines and antivi-
ral drugs might be ineffective and new approaches for the treatment influenza viruses should be considered. One 
of the most perspective approaches of antiviral treatment is based on the application of RNAi technology. RNAi is 
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a naturally occurring process of inhibition of gene expression which is closely connected with antiviral immunity. 
RNAi response is activated when short dsRNAs (~21 nucleotides in length), called short interfering RNAs (siR-
NAs) is incorporated into the enzymatic RNA induced silencing complex (RISC), where a helicase unwinds the 
duplex siRNA. The resulting antisense strand guides the RISC associated nuclease to its complementary mRNA, 
which will be cleaved7, preventing the synthesis of protein. The advantages of such RNAi therapeutics is their 
ability to target genes with great sequence homology.
The influenza A viruses are negative-sense, single stranded RNA viruses of orthomyxoviridae family. 
Influenza A genome consists of eight segments, which encodes 11 proteins8. The viral polymerase, consisting 
of three subunits, PA, PB1, and PB2, is responsible for replication and transcription, and hemagglutinin (HA) 
and neuraminidase (NA) are critical for viral entry and release. Following initial interaction of its HA with its 
N-acetylneuraminic (sialic) acid receptor on the cell surface, the virus enters the cell by receptor-mediated endo-
cytosis. Upon endosomal acidification, the HA protein undergoes conformational changes and mediates fusion 
between the viral envelope and endosomal membrane. The acidic environment of the endosome also triggers the 
disassembly of the viral core and the release of the viral ribonucleoprotein (rNP) into the cytoplasm of the cell9. 
Then, the rNPs are rapidly imported into the nucleus, catalyzing the viral genome replication and RNA transcrip-
tion10. Subsequently, newly formed rNPs, in association with other viral proteins are exported into the cytoplasm 
and transported to the cell membrane for budding and release. Almost every step and components of this com-
plex process of virus replication may be targeted with RNAi. The efficiency of such approach was demonstrated in 
several in vitro and in vivo models. Moreover, the application of siRNAs has been effectively demonstrated in the 
treatment of animals against pathogenic avian influenza A viruses of the H5 and H7 subtypes11–14.
Despite the great potential of RNAi technology, the main drawbacks that prevent the implementation of siR-
NAs into the clinical practice is associated with the problem of delivery. Due to the negative charge of RNA mol-
ecule, it is unable to be internalized into the cell cytoplasm. At the same time, it is rapidly degraded in biological 
fluids by endo- and exonucleases15. Several methods have been developed for in vitro and in vivo delivery of 
genetic materials, including siRNA16–18. Among them, the most effective is to use special carriers. But, for in vitro 
and in vivo application of carriers to deliver siRNA, three major criteria should be fulfilled. Such carrier should 
protect siRNA in intercellular matrices (biological fluids) against nucleases, provide transport across biological 
barriers (the plasma membrane) and exclude toxic or off-target effects. Frequently used non-viral carriers include 
lipoplexes and polyplexes19. Moreover, there are several commercially available carriers based on different cati-
onic polymers such as polyethylenimine (PEI), chitosan (CS), poly(L-lysine) (PLL), and poly(allylamine) (PAA)20, 
21. Apart from lipoplexes and polyplexes, polymeric or inorganic nano- and microparticles are currently being 
discussed as non-viral carriers for the delivery of siRNAs22–24.
Among the diversity of carriers, polyelectrolyte (PE) microcapsules prepared by the layer-by-layer (LbL) tech-
nique had been demonstrated as an unique tool for in situ encapsulation of the genetic materials to perform 
highly efficient in vitro delivery25–30. These capsules have many attributes that lend to their application in biomed-
icine. They are assembled under native conditions so that biologically active molecules are not chemically altered 
or inactivated. The meshwork of polymers formed in layer construction results in a structure that is permeable to 
small molecules. So an obvious use of microcapsules is as a delivery vehicle, and their permeable structure means 
they can act as a depot for release and they allow to control release of therapeutic agents at targeted places and at 
a desired time upon internal or external stimuli31–36. Also, incorporating metal nanoparticles in the microcapsule 
structure provides a target for heating using a laser, ultrasound or a high frequency alternating magnetic field, 
resulting in cargo release37–39. Nowadays, the use of sol-gel chemistry for the functionalization of PE microcap-
sules is a particular attractive aspect that could facilitate the development of PE microcapsules in biomedicine. 
Indeed, the sol-gel chemistry provides excellent opportunity to fabricate hybrid microcapsules with novel phys-
icochemical features, including a low permeability and intracellular degradation40, 41. Here, we focus on biode-
gradable polyelectrolytes and orthosilicate as sol-gel precursor for the formation of SiO2 shell onto the surface of 
microcapsule. Introduction of SiO2 nanostructures could significantly improve mechanical strength and stability 
of formed hybrid materials. Besides, the use of SiO2 can enhance the bioactive behavior of modified materials, 
due to the possibility to be easily internalized into cells and SiO2 can be dissolved in biological environments42.
In this work, we explored the combination of sol-gel coating with LbL method to enhance encapsulation effi-
ciency of siRNAs. Such hybrid capsules possess new morphological features and improved mechanical properties 
that protect from the decomposition of siRNA before reaching the target cells. To examine capsule internalization 
and cellular localization of siRNA, siRNA labeled by fluorescent marker was used. The uptake efficiency and 
cellular localization of fluorescently labeled siRNA was monitored using confocal laser scanning microscopy and 
flow cytometry. We demonstrated the feasibility for in vitro delivery of anti-viral siRNAs (NP-1155, NP-717 and 
NP-1496) using novel hybrid microcontainers. The reduction of viral nucleoprotein (NP) level and the inhibition 
of virus titers were observed after H1N1 virus infection in MDCK and A549 cells treated by different concentra-
tion of siRNA delivered via hybrid microcontainers. This study shows that microencapsulation technology for the 
delivery of antiviral siRNA is an efficient tool for silencing influenza virus infection and in development of siRNA 
delivery approach for combating viral infection diseases in humans.
Results and Discussion
Preparation of SiO2-coated hybrid capsules and their characteristics. The developing new strategy 
for siRNA delivery showing in virus gene silencing and a reduction of viral production is highly desirable. So, 
we examine the potency of novel microcontainers for delivery of antiviral siRNAs. We divided our research into 
several steps, including fabrication of hybrid microcarriers, evaluation of loading capacity for siRNA, capsules 
internalization, their toxicity and effect of encapsulated antiviral siRNAs on the inhibition of viral nucleoprotein 
and virus titer.
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Figure 1 shows the possible mechanism of antiviral siRNA delivery in the cell using hybrid microcarriers 
and simultaneously demonstrates the process of RNA interference for viral gene knockdown. At the first step, 
we have performed the modification of PE microcapsules using sol-gel chemistry (Fig. 2A). As shown in several 
papers34, 40, the integration of sol-gel method with LbL technique provides excellent opportunity to fabricate 
hybrid microcontainers with a drastically reduced permeability protecting bioactive molecules from premature 
degradation when it is internalized by the cells. To fabricate intracellular degradable capsules, we used PARG and 
DEXS polyelectrolytes and TEOS as sol-gel precursor to form biocompatible silica shell. After the several syn-
thetic procedures described in the experimental section (Preparation of SiO2-coated capsules and encapsulation 
of siRNAs), hollow SiO2-coated capsules were obtained. Figure 2B demonstrates the morphology of SiO2-coated 
capsules after sol-gel coating. In comparison with typical PE microcapsules made of PARG and DEXS (Fig. S1), 
the morphology of hybrid capsules has been obviously changed: these capsules are fully covered by a dense layer 
of SiO2 nanostructure, they became robust and remained spherical shape, which is due to the enhanced mechan-
ical properties of hybrid capsules. We further study the morphology and shell thickness of our hybrid capsules 
using transmission electron microscopy (TEM). As it can be clearly seen, TEM images of SiO2-coated capsules 
(Fig. 2C,D) clearly show the formation of hollow structure of composite capsules with shell thickness of ~100 nm. 
Importantly, the application of CaCO3 as template in co-precipitation process with bioactive compounds allows 
the in situ encapsulation of these substances without a loss of their bioactive properties because EDTA solution is 
Figure 1. The schematic illustration of the intracellular delivery of antiviral siRNA against influenza A virus 
using SiO2-coated hybrid capsules.
Figure 2. (A) The schematic illustration of the fabrication of SiO2-coated capsules and the encapsulation of 
antiviral siRNA. (B) SEM image of SiO2-coated capsules. (C,D) TEM images of hollow SiO2 -coated capsules.
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used for dissolution of CaCO342, 43. Whereas other templates are unable to apply because they can be removed only 
using calcination process, which would destroy the bioactive molecules upon high temperature. In addition, FTIR 
spectroscopy was used to confirm the successful SiO2 coating (Fig. S2). The FTIR spectrum of SiO2-coated cap-
sules demonstrates the characteristic bands which are typical for SiO2 nanostructure: a broad band in the range of 
3200–3500 cm−1 corresponds to the stretching vibrations of hydroxyl groups44. The peak at around 950 cm−1 can 
be assigned to Si–OH bending mode. The sharp peak at 1087–1095 cm−1 corresponds to Si–O–Si vibrations45. The 
above observation clearly shows that application of sol-gel coating does allow to fabricate well-defined spherical 
capsules with enhanced mechanical strength.
Loading efficiency of siRNAs. Next, we have compared the encapsulation capacity between SiO2-coated 
capsules and typical polymeric microcapsules made of PARG and DEXS. Also, we evaluate the localization of 
siRNA inside capsule using siRNA with fluorescent marker (PA-1630-FAM), which was monitored by confocal 
microscopy. Before LbL technique and sol-gel coating, we obtained the CLSM image of co-precipitated CaCO3 
particles containing PA-1630-FAM (Fig. 3A). As it can be seen, CaCO3 particles containing PA-1630-FAM exhibit 
green fluorescence. According to the co-precipitation process, a total loading efficiency of PA-1630-FAM was 
~95%. After LbL assembly of PARG and DEXS with following removal of CaCO3 by EDTA, we found out that 
(PARG/DEXS)3 microcapsules possess a poor green fluorescent shell (the PA-1630-FAM is localized on the pol-
ymeric shell of microcapsules) (Fig. 3B). Also the plot in panels below CLSM images of Fig. 3B represents the 
fluorescence intensity profile over (PARG/DEXS)3 microcapsule. After CaCO3 dissolution the major fraction of 
the PA-1630-FAM was released from microcapsule. The overall efficiency of encapsulated the PA-1630-FAM in 
(PARG/DEXS)3 capsules was 35% (Fig. 3D). This observation is in a good agreement with preciously reported 
results. M. Kakran et al. have also shown a low loading efficiency of RNA using polymeric capsules made of PARG 
and DEXS46. Then, we evaluated the storage capacity of hybrid capsules consisting of PARG/DEXS and SiO2 
nanostructure. We found that SiO2-coated capsules can load significantly more molecules of PA-1630-FAM than 
(PARG/DEXS)3 capsules. As shown in Figs 3C and S3, PA-1630-FAM is mainly localized inside hybrid capsule. 
The cumulative loss of encapsulated PA-1630-FAM in SiO2-coated capsules was around 29%, which considerably 
lower than found for (PARG/DEXS)3 capsules (~65%). Employing sol-gel coating allows to reduce the permeabil-
ity of hybrid capsules and, therefore, SiO2-coated capsules have ability to carry higher amount of siRNA compared 
Figure 3. Confocal microscopy analysis of distribution of PA-1630-FAM in used carriers: (A) CaCO3 
microparticles; (B) (PARG/DEXS)3 capsules; (C) SiO2-coated capsules. The plots below CLSM images are the 
representative fluorescence intensity profiles over the microcapsule. (D) Cumulative loss of PA-1630-FAM after 
dissolution of CaCO3 in SiO2-coated and (PARG/DEXS)3 capsules, respectively.
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to (PARG/DEXS)3 capsules. Introduction of silica shell reduced the pore diameter and enhanced mechanical 
properties of hybrid capsules, which is favorable for encapsulation of different bioactive compounds. In addition, 
we have confirmed the presence of encapsulated siRNA in hybrid microcapsules using acridine orange47. It is well 
known that acridine orange is a fluorescent dye that interacts with nucleic acids. In case of interaction with DNA, 
it exhibits an excitation maximum at 502 nm (cyan) and an emission maximum at 525 nm (green). In opposite 
when it binds with RNA, the excitation maximum is at 460 nm (blue) and the emission maximum is at 650 nm 
(red). This phenomenon is associated with electrostatic interactions occurring when the acridine molecule inter-
calates between the nucleic acid base pairs, and gives valuable information about the type of nucleic acid present. 
In our case, we observed a bright orange-to red fluorescence in the lumen of SiO2-coated capsules, indicating the 
presence of encapsulated RNA molecules inside hybrid capsules (Fig. S4). As revealed the crucial role of sol-gel 
coating on the increase of encapsulation efficiency of siRNAs, we then performed the encapsulation of other siR-
NAs (NP-1496, NP-1155 and NP-717) using LbL technique and sol-gel coating. The amount and concentration of 
all encapsulated siRNAs are presented in Table 1. Our data yielded that an average number of moles for all siRNA 
ranges from 0.41 × 10−3 to 0.56 × 10−3 pmol per capsule.
Capsules-to-cell interactions and distribution of PA-1630-FAM in the cells. The levels of cytotox-
icity, capsule internalization and transfection efficiency are key factors which should be considered for further in 
vitro application of our hybrid capsules for delivery of antiviral siRNAs. For this reason, fluorescent-tagged siRNA 
(PA-1630-FAM) was used to evaluate the capsule internalization and further cytosolic release of siRNA, as deter-
mined by CLSM. As for the study of internalization process and siRNA release, MDCK and A549 cell lines were 
used. MDCK and A549 cells were selected because they are two host cells easily infected by influenza A/PR/8/34.
First we examined MDCK and A549 cells incubated with non-encapsulated and encapsulated siRNA 
(PA-1630-FAM) to confirm the enhanced cellular uptake of FAM-labeled siRNA using SiO2-coated capsules. Both 
cells showed intense cytoplasmically localized fluorescence signal after 8 h incubation with SiO2-coated capsules 
containing FAM-labeled siRNA (Fig. 4). In contrast, there was very little uptake when cells were incubated with 
free FAM-labeled siRNA (PA-1630-FAM) in non-encapsulated form at the same time period.
We further studied the process of capsules internalization containing fluorescently labeled siRNA 
(PA-1630-FAM) and siRNA release into the cellular environment. At an initial time (t = 0 h), the SiO2-coated cap-
sules containing PA-1630-FAM were added to the cells at a capsules-to-cell ratio of 10:1 (Fig. 5A). It is important 
to mention that experiment was performed with adherent cell culture, imitating epithelial layer. At t = 0 h only 
green fluorescence from hybrid capsules can be observed. However, during the incubation period, the capsules 
mainly distributed in perinuclear compartment of the A549 cells and then began to decompose with follow-
ing release of PA-1630-FAM into the cytosol of the cells. Already after 4 h incubation, the distribution of the 
green fluorescent spots can be observed, indicating the release of PA-1630-FAM. CLSM images recorded after 8 h 
clearly demonstrate the increase in homogeneous distribution of the green fluorescence of PA-1630-FAM in the 
cytosol. At later time point (24 h) granular intracellular distribution pattern of the green spots can be observed. 
At the same time, the nuclei were not stained for each time points, indicating that PA-1630-FAM cannot cross 
the nuclear membrane. The same tendency in capsule internalization and the cytosolic release of PA-1630-FAM 
were found for MDCK cells (we refer the reader to the Supporting Information, Fig. S5). Using biodegradable 
polymers such as polyarginine or dextran sulphate in fabrication of microcapsules would permit degradation 
of the microcapsule structure46, resulting in the formation of hollow channels and structural disorder of hybrid 
capsules. This process may lead to decomposition of capsule shell and further release of PA-1630-FAM. At the 
same time, silica shell can be degraded in the cell medium42. Therefore, both factors (biodegradable polymers and 
silica shell) leads to the in vitro degradation of our hybrid capsules with further release of genetic materials. We 
suppose that due to the ability of degradable SiO2-coated capsules to encapsulate active siRNA, it makes SiO2 shell 
promising for the delivery of other sensitive compounds that can be decomposed before reaching the target cells.
The cellular uptake efficiency of fluorescent SiO2-coated capsules was further evaluated by flow cytometry. To 
facilitate siRNA internalization into the cells, the experiments were performed at 37 °C for 4 and 24 h respectively. 
The cells (MDCK and A549) were incubated with capsules at different capsules-to-cell ratios (1:1, 5:1 and 10:1). 
At definite time interval, the fluorescent intensity of cells with internalized capsules was measured. As shown in 
Fig. 5B, at capsules-to-cell ratio of 10:1 the peak of fluorescent intensity shifted to a higher level with increasing 
of time incubation: the percentage of A549 cells with internalized capsules increased from 61.5% in 4 h to 98.3% 
in 24 h, indicating the successful internalization of SiO2-coated capsules. Also, we can observe that the level of 
capsules internalization is growing with increase of capsules-to-cell ratio: around 98.3% of cells exhibited green 
fluorescence at capsules-to-cell ratio of 10:1 after 24 h incubation while cellular uptake percentage was only 56.4% 
at capsules-to-cell ratio of 1:1 for the same incubation period. The similar trend in cellular uptake was observed 




ncaps [pmol] (per 
capsule)
NP-1496 siRNA 1.80 0.41 × 10−3
NP-717 siRNA 2.00 0.45 × 10−3
NP-1155 siRNA 4.40 0.59 × 10−3
PA-1630-FAM 4.20 0.56 × 10−3
Table 1. Concentration and number of moles of siRNAs in SiO2-coated capsules. ncaps – number of moles of 
siRNA per capsule.
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Fig. 6S). These results clearly demonstrate that our hybrid capsules are readily internalized by both cell types. In 
contrast, A549 and MDCK cells treated with naked siRNA (PA-1630-FAM) show only ~1% naked siRNA uptake 
after 24 h incubation (Supporting Information, Fig. S7).
The in vitro cytotoxicity of SiO2-coated capsules at different capsules-to-cell ratios was also examined for 
both cell types. As shown in Fig. 5C, SiO2-coated capsules have shown negligible effect on viability of A549 cells. 
Indeed, SiO2-coated capsules at capsules-to-cell ratios of 1:1, 1:10, 1:50 do not seriously affect the viability of A549 
after 24, 72 and 96 hours incubation. At the capsules-to-cell ratio of 100:1, we observe a slight decrease in the via-
bility of A549. The high toxic effect was only detected when the number of capsules per a cell was more than 350. 
The similar tendency in cell viability was observed when MDCK cells were incubated with different concentration 
of capsules (Fig. S8). Therefore, the previously observed high cellular uptake efficiency of SiO2-coated capsules 
can be attributed to their low cytotoxicity. Thus, we may conclude that these capsules are non-toxic and possess 
biodegradable properties, which is in favor to use such microcontainers for further biological implementation 
and delivery of different bioactive compounds, including siRNA.
Effects of encapsulated siRNAs on the inhibition of viral nucleoprotein (NP) and influenza virus 
production. To determine the in vitro antiviral activity of three types of siRNAs (NP-1496, NP-1155 and 
NP-717) encapsulated inside SiO2-coated capsules, A549 and MDCK cells were used. The transfected cells were 
infected with influenza H1N1 virus. The direct ELISA analysis was used to detect viral nucleoprotein (NP) level 
in tested cell cultures while HA assay was employed to determine influenza virus titer in tested samples.
As we mentioned in the introduction section, the influenza A genome consists of eight RNA segments. Three 
of the eight RNA segments encode three components of the RNA transcriptase (PA, PB1 and PB2)48. The other 
additional RNA segments encode the nucleoprotein (NP), matrix protein, ion channel subunits, nonstructural 
proteins, major glycoproteins such as hemagglutinin and neuraminidase49. The schematic structure of influenza 
virus can be found in Supporting Information (Fig. S9). Recent studies have shown that NP genes play a crucial 
role in the virus replication, therefore, siRNAs against NP genes should inhibit influenza virus most effectively50. 
In our study, we used two new siRNAs (NP-1155 and NP-717) and one already known siRNA (NP-1496), spe-
cific for NP genes that can potentially inhibit influenza virus production. A phylogenetic alignment was used 
to define the conservative regions of 20–22 nucleotides that are potential targets for siRNAs in NP sequence. 
More than 9000 complete segment sequences of human influenza A virus NP genes were downloaded from the 
Figure 4. The uptake of fluorescently labeled siRNA (PA-1630-FAM) in MDCK (A) and A549 (B) cells in vitro. 
Confocal microscopy was used to compare the uptake and cellular localization of non-encapsulated and 
encapsulated siRNAs in SiO2-coated capsules after 8 h incubation with MDCK and A549 cells.
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NCBI’s Influenza Virus Resource51, aligned and determined short consensus sequences with highest conservation 
percentage. According to Tom Tuschl’s rules we designed siRNAs (NP-1155 and NP-717) specific for viral NP 
genes using Dharmacon’s siRNA design algorithm. Figure 6A shows the location of each tested siRNA in the viral 
genome. In the blast search at National Center for Biotechnology Information (http://blast.ncbi.nlm.nih.gov/
Blast.cgi), two siRNAs (NP-1155 and NP-717) are novel and none of them were found sequence homology with 
human genome or any other host genome. Only NP-1496 siRNA has been already tested for influenza A virus 
inhibition and was shown as good silencer of NP gene and virus inhibitor48.
Employing direct ELISA analysis, three types of siRNAs encapsulated inside SiO2-coated capsules (the con-
centration of each encapsulated siRNA in capsules is shown in Table 1) were examined if they can reduce viral 
NP level in infected cells. For this experiment, SiO2-coated capsules containing antiviral siRNA were introduced 
Figure 5. (A) CLSM images demonstrating the intracellular release of PA-1630-FAM from SiO2-coated 
capsules and further PA-1630-FAM distribution in A549 cells at different incubation period. (B) Flow 
cytometry analysis of SiO2-coated capsules uptake in A549 cells at different capsules-to-cell ratio and incubation 
time. (C) Cell viability of A549 cells incubated with SiO2-coated capsules at different capsules-to-cell ratios for 
various time intervals (24, 48, or 72 hours).
www.nature.com/scientificreports/
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into the suspension of cells (~1 × 105) to generate the systems with 50, 250 and 500 pmol of encapsulated siRNA 
respectively. After 24 h incubation the cells were washed with PBS to remove non-uptake capsules and then were 
infected with H1N1 A/PR/8/34 virus at an infectious doze (moi) of 0.01. At 72 h post-infection, culture superna-
tants were harvested to determine the virus NP level. As for negative control, the cells without incubation with 
capsules were used. The presence of encapsulated siRNA transfected into the cells during the incubation period 
(from 4 to 72 h) was confirmed by gel-phoresis (Fig. 6B). For all time points siRNA is stable and not degraded 
during the incubation process. The results of ELISA analysis showed that the amount of viral NP production 
in cells incubated with SiO2-capsules containing antiviral siRNAs is remarkably lower than for the control cells 
(Fig. 6C). The viral NP production decreased at different dose of siRNAs. It indicates that siRNAs delivered 
via SiO2-coated capsules affect virus protein synthesis. For comparison, ELISA experiment was conducted with 
siRNA/PEI polyplexes containing the same amount of NP-1496 siRNA (Fig. 6C). The resulting viral NP level was 
higher in comparison with SiO2-coated capsules at an equivalent concentration of NP-1496 siRNA, confirming 
the vital role of SiO2-coated capsules in delivery of antiviral siRNA affecting on virus protein synthesis.
The next experiment was conducted using HA assay to demonstrate that the siRNA delivered by SiO2-coated 
capsules was superior to siRNA/PEI polyplexes. The NP-1496 siRNA was chosen for this experiment because of a 
high potency of NP-1496 siRNA in inhibiting influenza virus production as it was previously demonstrated48. In 
this experiment, NP-1496 siRNA (50–250 pmol) delivered by SiO2-coated capsules was compared with siRNA/
PEI polyplexes in terms of their ability to inhibit H1N1 replication in A549 cells (1 × 105). The siRNA delivery was 
achieved before the virus infection. At 72 h after virus infection, the cell pellets was used to determine the virus 
titer. The A549 cells with H1N1 influenza virus (cells + virus) was used as a negative control. As it can be clearly 
seen in Fig. 6D, the NP-1496 siRNA delivered by SiO2-coated capsules reduced the viral titer more effectively 
Figure 6. (A) Schematic diagrams showing the location of each siRNA in the viral genome. (B) Results of 
electrophoresis of the NP-1496 siRNA PCR products extracted from MDCK cells. (C) ELISA analysis showing 
the reduction of viral NP level in infected A549 cells treated with different anti-viral siRNAs in encapsulated 
form (50 pmol–1 capsule/cell; 250 pmol–5 capsules/cell; 500 pmol–10 capsules/cell). (D) Comparison of 
antiviral effect of NP-1496 siRNA delivered by siRNA/PEI polyplexes and SiO2-coated capsules (50 pmol–1 
capsule/cell; 250 pmol–5 capsules/cell; 500 pmol–10 capsules/cell). (E) Inhibition of influenza virus 
production by different dose of siRNAs in encapsulated form. Viral titers was measured 72 h after infection in 
a hemagglutination assay. The data are presented as means ± standard deviation (SD) from three independent 
experiments. Note that some hemagglutination unit values were identical for the triplicate experiments, and so 
standard deviation values are 0.
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compared to the NP-1496 siRNA/PEI polyplexes delivery method. These findings result in an enhanced antiviral 
effect of NP-1496 siRNA in inhibiting H1N1 influenza virus titer in A549 cells. Also, the therapeutic potency of 
antiviral siRNA delivery by SiO2-coated capsules has been shown on the example of MDCK cells. (Supporting 
Information, Fig. S10 and Table S1).
Then, we compared the antiviral activity of three siRNAs (NP-1155, NP-717 and NP-1496) delivered by 
SiO2-coated capsules (Fig. 6E). According to the previous observation, the optimum amount of siRNA was 250–
500 pmol for 1 × 105 cells48. In case of NP-1496 siRNA-SiO2-coated capsules, we can observe 2-fold decrease in 
virus titer compared with control (cells + virus). The NP-1155 siRNA demonstrates 4-fold decrease in virus titer. 
The transfection with NP-717 siRNA-SiO2-coated capsules was the most effective, resulting in 8-fold decrease of 
virus titer. Among tested siRNAs, two novel siRNAs (NP-1155 and NP-717) demonstrated the inhibition of virus 
production in dose-dependent manner.
The siRNAs delivery using hybrid microcarriers has the considerable therapeutic potential for treating and 
prevention of influenza virus infection. We suppose that application of hybrid microcarriers for in vitro delivery 
of anti-viral siRNAs can be considered as more promising approach than well-known physical methods of RNA 
delivery such as electroporation. Although electroporation has been used for in vitro delivery of anti-viral siRNA 
into the cells, leading to inhibition of viral replication48, but this method often leads to cell death since the electri-
cal fields cause permanent permeable state of the membrane and, hence, the consequent loss of cell homeostasis52. 
As shown, our capsules possess very low toxicity and, therefore, can be considered as more promising delivery 
vehicles in comparison with PEI/siRNA polyplexes is significantly more toxic than our capsules. Although, PEI/
siRNA polyplexes can also deliver siRNA resulting in the reduction of virus production. But, the further increase 
of concentration of PEI/siRNA polyplexes in order to generate high amount of siRNA leads to significant reduc-
tion of the cell viability: it requires more than 2 ng/μL of PEI for loading 500 pmol of siRNA which is highly 
toxic (Supporting Information, Fig. S11). Therefore, it limits the application of PEI/siRNA polyplexes for clinical 
implementation.
Conclusions
In this study, we demonstrated that hybrid microcarriers made of SiO2 nanostructures and polypeptides/polysac-
charides provides a significant increase in encapsulation efficiency of siRNA. The Advantage in combination of 
the unique structural properties of SiO2 with LbL technique paves an efficient strategy platform for the fabrication 
of stable and safe microcontainers with a low permeability and, protecting from premature decomposition of 
siRNA before reaching the target cells. Due to the biodegradable ability of obtained hybrid capsules, the siRNA 
can release into the cytosol of the cells after capsules internalization. In vitro experiments have also confirmed that 
these capsules are not toxic, producing the high local concentration of siRNA in the cells. This siRNA delivery sys-
tem was proved to work for both cell lines (MDCK and A549). Anti-viral activity of two novel siRNAs (NP-1155 
and NP-717) and NP-1496 siRNA using SiO2-coated capsules was tested to successfully serve as viral carriers for 
the in vitro delivery. We found that NP-717 effectively reduced the NP as well as virus production. Other siRNAs 
(NP-1155 and NP-1496) also show some inhibitory effect after virus infection. These findings have significant 
implications for the use of microencapsulation technology for effective delivery of siRNAs in therapy of influenza 
virus infection. The new RNAi delivery system will allow us to follow up further in vivo investigations.
Methods
Materials. Poly-L-arginine hydrochloride (PARG, MW > 70 000), Dextran sulfate (DEXS, MW > 500 000), 
Tetraethyl orthosilicate (TEOS, MW = 208.33, 99.9%), Polyethylenimine (PEI, MW ~25 000), calcium chloride 
dehydrate, anhydrous sodium carbonate, ethylenediaminetetraacetic acid trisodium salt (EDTA) were obtained 
from Sigma-Aldrich and used without further purification. Absolute ethanol (C2H5OH, 98%) was used in sol-gel 
synthesis. Deionized (DI) water with specific resistivity higher than 18.2 MΩcm from a three-stage Milli-Q Plus 
185 purification system was used.
siRNAs. All RNA oligonucleotides were synthesized by “DNA-synthesis” (Moscow, Russian 
Federation). The sequences of all tested siRNAs were the following: NP-1496 siRNA (sense 
5′-ggAUCUUAUUUCUUCggAgdTdT-3′; antisense 5′-CUCCgAAgAAAUAAgAUdTdT-3′); NP-717 siRNA 
(sense 5′-UUAUgAgAgAAUgUgCAACAU-3′; antisense 5′-gUUgCACAUUCUCUCAUAAgC-3′); NP-1155 
siRNA (sense 5′-AAUUgCUUCAAAUgAgAACAU-3′; antisense 5′-gUUCUCAUUUgAAgCAAUUUg-3′). In 
addition, the modified RNA oligonucleotides NP-1496-1/2, in which the 2_-hydroxyl group was replaced into a 
2_-O-methyl group in every nucleotide residue, and single strand PA-1630-FAM, containing carboxyfluorescein 
(FAM) on its 3′-end, were also synthesized by “DNA-synthesis”. The sequence of PA-1630-FAM with fluorescence 
marker was the following: sense 5′-UgAgCCACACAAAUgggAA-3′; antisense 5′-UCCCAUUUgUgUggCUCUU-
*FAM-3′. The oligonucleotides were dissolved in depcH2O (100 uM), aliquoted and stored at −20 °C. For exper-
imental exposure required amount of complementary single strand oligonucleotides were mixed and annealed 
by heating first to 95 °C for 5 min, then hybridized in the temperature mode: slowly reducing the temperature by 
1 °C every 30 sec until 35 °C, then by 1 °C every 1 min until 5 °C. The resulting siRNA duplexes were analyzed by 
15% PAAG electrophoresis.
Preparation of SiO2-coated capsules and encapsulation of siRNAs. The CaCO3 microparticles were 
used as cores and prepared according to the previously reported method53. Then, CaCO3 particles were suspended 
in an aqueous solution of PARG (1 mg/mL) containing 0.15 M NaCl. The PARG was allowed to adsorb onto CaCO3 
particles for 10 min. Next, the dispersion was centrifuged and washed three times with deionized water to remove 
non-adsorbed polyelectrolyte. After that, the deposition of DEXS was carried out on the PARG-coated CaCO3 
particles using the same manipulation. Such procedure of PARG/DEXS assembly was repeated several times in 
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order to form core-shell structure with following shell architecture: (PARG/DEXS)2 + PARG54. Termination of 
capsule preparation by PARG is very important due to further SiO2 coating. Afterwards, core-shell particles were 
centrifuged and washed three times in deionized water. In the second step, sol-gel approach was applied for SiO2 
coating. Before sol-gel synthesis, core-shell particles were dispersed in 4 mL of ethanol and ultrasonically treated 
for 3 min in ultrasonic bath. Then, this suspension was mixed with 17.5 mL of water-ethanol solution (77%) and 
100 μL of TEOS was added. The obtained mixture was stirred for 20 min with following addition of 200 μL of 
ammonia solution (25%). The final suspension was stirred for 3 hours at room temperature. Finally, the sample 
was centrifuged and washed three times with deionized water. The dissolution of CaCO3 template was accom-
plished by exposure of the sample to 0.2 M EDTA aqueous solution. Finally, hollow SiO2-coated capsules were 
fabricated. Typically obtained amounts of SiO2-coated capsules from one synthesis were 4.4 ÷ 7.4 × 106 capsules.
To perform in situ encapsulation procedure of siRNAs, 120 μL of used siRNA (PA-1630-FAM, NP-1496, 
NP-717 and NP-1155) with concentration of 100 pmol/μL has been co-precipitated with CaCO3 particles follow-
ing the multilayer assembly of PARG/DEXS. This procedure is similar to already reported on nucleic acid encap-
sulation via CaCO3 templating55. In our work, the obtained core-shell particles containing siRNA molecules were 
used for sol-gel coating as described above. The encapsulation efficiency of siRNAs was measured by absorbance 
at 260 and 280 nm using the Nanodrop 2000 Spectrophotometer. The final amount of each encapsulated siRNA 
are enlisted in Table 1. The cumulative loss of PA-1630-FAM was calculated as the difference between the initial 
amount of siRNA and the amount of siRNA in the supernatant after core dissolution.
Characterization of SiO2-coated capsules. The morphology of SiO2-coated capsules was observed on 
SUPRA 55VP Scanning Electron Microscope (SEM ZEISS, Germany) at an accelerating voltage of 15 kV. Before 
SEM analysis, the diluted ethanol suspension of SiO2-coated capsules was dropped on a glass slide, air dried, and 
coated with gold (Au) before observation. Further, the morphology and shell thickness were studied using a JEOL 
JEM-2100F transmission electron microscope (TEM). The SiO2-coated capsules were also observed using LSM 
880 Confocal Laser Scanning Microscope, Carl Zeiss, Germany.
Viruses and titer assays. Influenza virus subtype H1N1 A/PR/8/34 (PR8) from Influenza Research 
Institute collection (St-Petersburg, Russia) were grown in the allantoic cavity of 10-day-old embryonated chicken 
at 37 °C. Allantoic fluid was harvested 48 h after virus inoculation and stored at −80 °C. Virus titer was measured 
by hemagglutination assay, using 50% tissue culture infective dose (TCID50) assay. Serial 10-fold dilutions of 
allantoic fluid were added onto a monolayer of MDCK and A549 cells in 96-well culture plates and incubated for 
three days. The viral titer for each sample was calculated by the Reed–Muench method56.
The hemagglutination assay (HA) was carried out in U-bottom 96-well plates in order to evaluate the virus 
titer. Serial 2-fold dilutions of supernatants were mixed with an equal volume of a 0.5% suspension (vol_vol) 
of chicken erythrocytes and incubated on ice for 30 min. Wells containing an adherent, homogeneous layer of 
erythrocytes were scored as positive.
Cell Culture and incubation of the cells with SiO2 -coated capsules. Madine-Darby canine kidney 
(MDCK) and human lung epithelial (A549) cells were kindly provided by the colleagues from Influenza Research 
Institute collection (St-Petersburg, Russian Federation). Cells were cultivated in cultural flasks using Dulbecco’s 
Modified Eagle Medium (DMEM) (Lonza, Switzerland); supplemented with 100 IU/ml penicillin, 0.1 mg/ml 
streptomycin (Biolot, Russia), and 10% Fetal Bovine Serum (FBS) (Hyclone, USA). After achievement of conflu-
ence (>80%), cells were detached with trypsin/EDTA solution (Invitrogen, USA) for 10 min and were seeded on 
cultural flasks at a density of 5.0 × 103 cells/cm2.
We encapsulated PA-1630-FAM in order to monitor the release behavior of bioactive molecules from 
SiO2-coated capsules in the cells using CLSM. The capsules with PA-1630-FAM were added to suspensions of 
A549 and MDCK cells at a capsule-to-cell ratio of 10:1 and seeded in culturing flasks at a density of 5,0 × 103 cells/
cm2 at 37 °C for 4, 8 and 24 h. At definite time points, the cells were viewed under CLSM (Carl Zeiss, Germany) 
with 40x and 63x high numerical-aperture oil immersion objectives. The uptake behavior of SiO2-coated capsules 
containing PA-1630-FAM by MDCK and A549 cells was evaluated using flow cytometry (FACS Aria, BD, USA). 
The hybrid capsules were incubated with the cells for 24 at different capsules-to-cell ratios (1:1, 5:1 and 10:1).
Virus Infection. For siRNAs introduction, the SiO2-coated capsules containing anti-viral siRNA (NP-1496, 
NP-1155 or NP-717) were added to cells in the monolayer in the 24x well plate (105 cells per well). After 24 h 
incubation, the cells were washed with PBS solution to remove non-uptake capsules. Then, 0.01 moi of PR8 virus 
in infection medium αMEM + L-glutamine, consisting trypsin TPCK 0.1 ug/ml and 100 ug/ml streptomycin was 
added to each well. After 1 h incubation at 8 °C, the infectious medium was washed and the same medium without 
virus was added. The cells were cultured at 37 °C under 5% CO2. At definite time period after infection (72 hours), 
the supernatants were harvested from infected cultures and the virus titer was determined.
Cell viability assay. The SiO2 -coated capsules were added and incubated with MDCK and A549 cells for 
24 h. The cell viability was defined by differential counting in hemocytometer using vital staining with trypan 
blue. Briefly, after 24 hours incubation, culture medium that contained detached cells were harvested, adherent 
fraction of cells were detached by trypsin/EDTA solution and mixed with previously described portion of culture 
medium, so the all fractions of cells were represented in further analysis. For analysis, 20 μL of cell suspension 
were mixed with same amount of 0, 4% trypan blue (Vecton, Russia) solution. Stained cells were analyzed ex 
temporo, cells free of dye were counted as viable.
Direct enzyme-linked immunosorbents assays (ELISA). After 72 hours post infection, the super-
natants were removed from the cells. The viral nucleoprotein (NP) level was determined using direct ELISA 
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analysis with streptavidin-HRP-conjugated mouse antibody targeted viral NP (prepared by Influenza Research 
Institute). The cells were fixed with 80% cold acetone for 1 h and washed three times with phosphate buff-
ered saline with 0.05% Tween (PBST), then incubated with 5% milk dissolved in PBST, washed three times. A 
streptavidin-HRP-conjugated mouse anti-NP antibody was added to each well at 1:5000 concentration and incu-
bated at 37 °C for 1 h. Immunoreactivity was analyzed by adding to the samples TMB Peroxidase EIA Substrate 
Kit (Bio-Rad) according to manufactures protocols. Absorbance correlated with amount of target nucleoprotein 
in cells was measured on multifunctional reader CLARIOstar®(BMG LABTECH, Germany).
RNA isolation, reverse-transcription, and quantitative real-time-polymerase chain reaction 
(qRT-PCR). To confirm the presence of siRNA in the cells, we used qRT-PCR. The MDCK cells after incu-
bation with SiO2-coated capsules containing siRNA in 6x well plate were harvested with trypsin-EDTA solution 
and miRNA fraction was extracted using the mirVana™ miRNA Isolation Kit (Invitrogen, USA) according to the 
manufacturer’s instructions. Then extracted RNA was treated with mirVana™ qRT-PCR miRNA Detection Kit 
(Invitrogen, USA) according to the manufacturer’s instructions.
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